Future roles for liquid biopsies in clinical decision making in uro-oncology

Highly-regarded experts of the EAU Section of Urological Research (ESUR) will share vital research and their valuable insights with you in detail.

Although molecular analysis of tumour tissues is still the standard in personalized oncology, the focus is increasingly turning to liquid biopsy. It represents the next frontier for diagnosis, management, and follow-up for solid malignancies. During this course, the current status and future perspectives of liquid biopsies will be presented. Furthermore, specific topics in urological malignancies will be addressed. Here, circulating tumor DNA (ctDNA) is one of the most promising markers in blood and urine from patients with bladder and prostate cancer to guide our therapy decision in the near future. In addition, the distinguished possibilities to use urine markers in urothelial cancer patients will be discussed.

K. Junker, Homburg (DE)
G. Jenster, Rotterdam (NL)
K. Pantel, Hamburg (DE)
L. Dyrskjøt, Aarhus (DK)
K.E.M. Van Kessel, Rotterdam (NL)

At a glance

Publication date: February 2021
Available languages: English
Topic: Uro-oncology
CME: 1 European CME credit (ECMEC)
Duration: approx. 60-90 minutes